1. Home
  2. GILT vs BMEA Comparison

GILT vs BMEA Comparison

Compare GILT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

N/A

Current Price

$11.47

Market Cap

747.5M

Sector

Technology

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.40

Market Cap

96.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GILT
BMEA
Founded
1987
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
747.5M
96.9M
IPO Year
1993
2021

Fundamental Metrics

Financial Performance
Metric
GILT
BMEA
Price
$11.47
$1.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$16.00
$8.71
AVG Volume (30 Days)
504.3K
1.7M
Earning Date
11-12-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
42.22
N/A
EPS
0.41
N/A
Revenue
$392,826,000.00
N/A
Revenue This Year
$49.48
N/A
Revenue Next Year
$13.61
N/A
P/E Ratio
$28.37
N/A
Revenue Growth
29.68
N/A
52 Week Low
$5.30
$0.87
52 Week High
$15.24
$6.06

Technical Indicators

Market Signals
Indicator
GILT
BMEA
Relative Strength Index (RSI) 42.28 55.55
Support Level $11.45 $0.95
Resistance Level $13.08 $1.56
Average True Range (ATR) 0.48 0.14
MACD 0.05 0.04
Stochastic Oscillator 12.75 73.77

Price Performance

Historical Comparison
GILT
BMEA

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: